Lecanemab Frequently Asked Questions

Introducing “Lecanemab Frequently Asked Questions“: On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and Biogen, for the treatment of early-stage Alzheimer’s disease. Lecanemab, administered through intravenous infusion every two weeks, is a monoclonal antibody designed to bind and remove amyloid plaques in the brain, which are associated […]

Read More…

Academics - Marymount University